1012P - A multi-institutional dose-finding and efficacy confirmation trial of superselective intra-arterial infusion of cisplatin and concomitant radiother...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Anticancer Agents
Head and Neck Cancers
Surgical Oncology
Biological Therapy
Radiation Oncology
Presenter Tomohiro Sakashita
Citation Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376
Authors T. Sakashita1, A. Homma1, R. Onimaru2, K. Matsuura3, H. Shinomiya4, R. Hayashi5, K. Shiga6, H. Tachibana7, K. Nakamura8, J. Mizusawa9, M. Fujii10
  • 1Otolaryngology-head And Neck Surgery, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 2Radiology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 3Head And Neck Surgery, Miyagi Cancer Center, Natori/JP
  • 4Otolaryngology-head And Neck Surgery, Kobe University Graduate School of Medicine, Kobe/JP
  • 5Head And Neck Surgery Division, National Cancer Center Hospital East, Kashiwa/JP
  • 6Otolaryngology - Head And Neck Surgery, Iwate Medical University School of Medicine, Morioka/JP
  • 7Radiation Oncology, Aichi Cancer Center Hospital, Nagoya/JP
  • 8Japan Clinical Oncology Group Operations Office, National Cancer Center Hospital, Tokyo/JP
  • 9Jcog Data Center/operations Office, Center For Research Administration And Support, National Cancer Center Hospital, Tokyo/JP
  • 10Otorhinolaryngology, National Tokyo Medical Center, Tokyo/JP



Superselective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy (RADPLAT) has been performed for the patients with locally advanced maxillary sinus squamous cell carcinomas (LA-MSSCCs) in several institutions and has been reported to result in a favorable survival. This multi-institutional prospective trial was aimed to confirm the adequate dose and efficacy of RADPLAT for the patients with LA-MSSCCs. The dose-finding phase was performed to evaluate the incidence of dose-limiting toxicity (DLT) and to determine the recommended cycle of intra-arterial infusion of cisplatin.


Eighteen patients were registered from 7 institutions for this study. In this dose-finding study, 100 mg/m2 of cisplatin was administered intra-arterially weekly for 7 weeks with concomitant radiotherapy (total 70 Gy). Cisplatin was skipped in the case of adverse events that met the skipping rule defined by the protocol. The recommended number of cycles was determined according to the distribution of the number of cycles of administered cisplatin and the incidence of DLT.


The median age of all participants was 64 years old (range, 40-75 years old). Sixteen patients were diagnosed as T4aN0M0, and two patients as T4bN0M0. All patients achieved full dose of radiotherapy. The number of cycles of administered cisplatin was 7 in 13 patients and 6 in 5. DLT was observed in 5 patients; Gr 3 liver dysfunction (1), Gr 4 thrombocytopenia (1), Ccr 


RADPLAT appears to be safe and well-tolerated at 7 cycles of cisplatin at a dose of 100 mg/m2 each cycle, which were determined to be the recommended number of cycles for LA-MSSCC.

Clinical trial identification


Legal entity responsible for the study



Research Funding Source Name: the Practical Research for Innovative Cancer Control(15ck0106137h0002)


All authors have declared no conflicts of interest.